Earlier this year, Boston Scientific Corporation (NYSE: BSX) acquired two companies: Cosman Medical Inc. to strengthen its neuromodulation business and EndoChoice Holdings Inc. to strengthen its pathology services and imaging technologies.
Since then, the medical device giant has toned down its acquiring habits with two asset/portfolio purchases in November.
On November 3, 2016, the company acquired the LumenR™ Tissue Retractor System from LumenR LLC. It is currently in development for use during endoscopic resection of lesions in the colon, esophagus or stomach. Boston Scientific will conduct additional development and evaluation of the system prior to commercialization.
On November 15, 2016, it acquired the gynecology and urology portfolio from Distal Access, LLC. The portfolio includes the Resectr™ Tissue Resection Device, a single-use solution designed to effectively remove uterine polyps. The Resectr device will be integrated into the Boston Scientific urology and pelvic health business which offers minimally invasive solutions for gynecologic surgery, including the Symphion™ System for uterine tissue removal and Genesys HTA™ System for the treatment of abnormal uterine bleeding.
These asset purchases strengthen Boston Scientific’s minimally invasive capabilities within its gastrointestinal pipeline and its urology and pelvic health business.